ILpress February 2016

WuXi Collaboration with Israeli Partners

The Future of Cancer Therapy: An Interview with Yinon Ben-Neriah, Hebrew University

WuXi News

Dr. Ge Li Receives Executive of the Year Award from SCRIP

Over 1,100 Executives Signed-up for 4th Annual WuXi Global Forum at J.P. Morgan Conference

WuXi Healthcare Ventures Joins Financing Rounds for Twist Bioscience and Syros Pharmaceuticals

WuXi Plans $120 Million Investment in New Integrated Biologics Solution Center to Expedite Biologics Development from Ideas to Clinic

WuXi and MedImmune Form a Strategic Alliance to Develop Innovative Biologics in China for AstraZeneca

WuXi Healthcare Ventures II Closes with Oversubscription

WuXi Congratulates MSD on Receiving FDA Approval of ZEPATIER™

Congratulations to Chia Tai Tianqing Pharmaceutical Group and Janssen for Licensing Agreement
Perspectives

Combining Service and Investment: An Interview with Wei Li, Co-Founder of WuXi Healthcare Ventures

Developing a Novel ADC for Global Market via Innovative Three-party Collaboration – An Interview with Dr. Jiawen Han, Vice President, WuXi Biologics

Meet IDSU Leadership: An Interview with Tao Guo, VP of Medicinal Chemistry
In This Issue
Industry Beats

TAU links growth factor to development of Alzheimer’s disease (Source: Tel Aviv University)BioLight Reports Positive Second Clinical Study Results for its TeaRx Multi-Assay Test for Dry Eye Syndrome (Source: PR Newswire)Israeli Pharma Firm to Develop Alternative to Viagra (Source: The Times of Israel)Israeli Researchers Develop Novel Method To Treat Aggressive Blood Cancers (Source: No Camels)Breakthrough Israeli Research Improves HIV/AIDS Treatment, Could Lead To Cure (Source: No Camels)CollPlant Reports Positive Interim Trial Results for Vergenix, Indicated for the Treatment of Tendinopathy (Source: CollPlant)Can-Fite Announces 2016 Clinical Milestones for its Pipeline of Drugs in Six Indications (Source: Can-Fite)Compugen Achieves Third Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer (Source: Compugen)

Kamada’s Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment (Source: Kamada)

Teva Announces Launch of Generic Ortho Tri-Cyclen® Lo in the United States (Source: Teva Pharmaceuticals)

Kite Pharma Expands Its Clinical and Research Partnership With the National Cancer Institute (NCI) for Next-Generation CAR Programs to Treat B-Cell Malignancies (Source: Kite Pharma)

BioLineRx Announces Collaboration with MSD to investigate the combination of KEYTRUDA (pembrolizumab) and BL-8040 in Pancreatic Cancer (Source: BioLineRx)

Sanara Ventures Cements Teva-Philips Ties (Source: Sanara Ventures)

J&J Backs Israeli Startup in $28M Round for Heart Failure Implant (Source: Fierce Medical Device)

Phillip Morris Invests $20m in Syqe Cannabis Inhaler (Source: iCAN)

Takeda Provides Further Information about its New Business Venture with Teva (Source: Takeda)

Adicet Bio Announces Closing of $51 Million Series A Financing and Acquisition of Applied Immune Technologies (Source: PR Newswire)

CartiHeal Raises $15 Million (Source: PR Newswire)

Insightec Secures $22 Million and Appoints Maurice R. Ferre, MD, as CEO (Source: Insightec)

Israeli Catheter Co Pi-Cardia Raises $10m (Source: Globes)

KAHR Medical Reports Raising $12M At First Closing Of Its Series B Private Equity Financing (Source: KAHR Medical)

Drug Approvals & Designations

Upcoming Events

February 22-23, 2016
Tel Aviv University, Tel Aviv
 
March 9, 2016
Independence Park, Tel Aviv
 
March 29, 2016
The Hebrew University of Jerusalem, Jerusalem
Follow us on TwitterView our profile on LinkedIn

MApress December 2015

WuXi Boston Holiday Party

WuXi Boston celebrated the holidays with clients and colleagues on Tuesday, December 15, at Viale Restaurant in Cambridge. The evening brought out over 100 representatives from the many research institutes and pharma, biotech, and VC companies in the area. Thanks to all attendees who made it a great night filled with inspiring conversation and festive joy to bring in the new year!
WuXi News

WuXi and MedImmune Form Strategic Alliance to Develop Innovative Biologics in China for AstraZeneca

Dr. Ge Li Receives Executive of the Year Award from SCRIP

WuXi Global Forum 2016 at J.P. Morgan Conference

WuXi Healthcare Ventures II Closes with Oversubscription

WuXi and Lilly Collaborate to Develop Novel Therapeutics in China

Gilead Sciences and WuXi Partner for a Dedicated Analytical and Stability Testing Facility

Cancer, Meet the Alamo: San Antonio Enlists WuXi NextCODE to Speed Unparalleled Open-access Cancer Genome Project

Congratulations to Novira Therapeutics for its Acquisition Agreement with Johnson & Johnson
Innovation That Matters

Combating the Hep B Virus: An Interview with George Hartman, Novira Therapeutics
Perspectives

Combining Service and Investment: An Interview with Wei Li, Co-Founder of WuXi Healthcare Ventures

Developing a Novel ADC for Global Market via Innovative Three-party Collaboration – An Interview with Dr. Jiawen Han, VP of WuXi Biologics

Prospects for Cell and Gene Therapy: An Interview with Alan Moore, VP of Strategic Accounts and Cell Manufacturing

Meet IDSU Leadership: An Interview with Tao Guo, VP of Medicinal Chemistry
In This Issue
Industry Beats

Gurnet Point Capital Launches New Drug Development Company, Boston Pharmaceuticals (Source: Business Wire)

Avedro Completes New $32 Million Round of Financing (Source: Avedro)

FDA Approvals & Designations

Upcoming Events

January 21, 2016
Mass Bio, 300 Tech Square, Cambridge, MA
January 21-22, 2016
Courtyard Boston Logan Airport Hotel
February 3, 2016
Princeton, MA
February 23-26, 2016
Boston, MA
WuXi AppTec
222 Third Street, Suite 1100
Cambridge, MA 02142
857-242-3984
Follow us on TwitterView our profile on LinkedIn

BAYpress January 2016

 

WuXi News

Over 1,100 Executives Signed-up for WuXi Global Forum during J.P. Morgan Conference

WuXi Healthcare Ventures Joins Financing Round for Twist Bioscience

Dr. Ge Li Receives Executive of the Year Award from SCRIP

WuXi and MedImmune Form a Strategic Alliance to Develop Innovative Biologics in China for AstraZeneca

WuXi Plans $120M Investment in New Integrated Biologics Solution Center to Expedite Biologics Development from Ideas to Clinic

Innovation That Matters

Combatting the Hep B Virus: An Interview with George Hartman, Novira Therapeutics 
Perspectives

Combining Service and Investment: An Interview with Wei Li, Co-Founder of WuXi Healthcare Ventures

Developing a Novel ADC for Global Market via Innovative Three-Party Collaboration: An Interview with Jiawen Han, VP of WuXi Biologics
In This Issue
Industry Beats

Top 20 Life Science Start-ups to Watch in the U.S. (Source: Biospace)DNAnexus In Real Life: Tackling Precision Medicine Through Real-Time, Multi-Institution Cancer Collaboration (Source: DNAnexus)Adicet Bio Raises $51M, Makes Acquisition, as it Works on Cancer Therapy (Source: Silicon Valley Business Journal)Iconic Therapeutics Raises $40M for Eye Disease R&D (Source: Iconic Therapeutics)Kodiak Sciences Closes Series B Financing to Fuel Retina Pipeline (Source: Kodiak Sciences)

MedImmune and UCSF Announce Seven-Project Partnership (Source: GEN)

Dementia Discovery Fund Chooses Alector for First Investment – San Francisco-based Alector’s Research Focuses on Eradication of Brain Plaque by Immune System (Source: WSJ)

Oracle Sets Sights on Genetic Testing with New Precision Medicine Business (Source: Biospace)

Cortexyme Raises $15M Series A to Advance Development of Novel Therapeutics and Diagnostics for Alzheimer’s Disease (Source: Cortexyme)

Solstice Biologics Raises $4M (Source: Biospace)

University of California Investing $250M in Start-ups (Source: TechCrunch)

FDA Approvals & Designations

Upcoming Events

February 25-26, 2016
CLSA
South San Francisco, CA
March 6-11, 2016
San Francisco, CA

Please feel free to send us your company news and events.  We would be delighted to share it with our Bay Area community. 
Follow us on TwitterView our profile on LinkedIn